1. Market Research
  2. > Pharmaceutical
  3. > OTC Market Trends
  4. > MK-1602 (Migraine) - Forecast and Market Analysis to 2023

MK-1602 (Migraine) - Forecast and Market Analysis to 2023

  • March 2014
  • -
  • GlobalData
  • -
  • 56 pages

Summary

Table of Contents

MK-1602 (Migraine) - Forecast and Market Analysis to 2023

Summary

The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.

MK-1602, under development by Merck, is a calcitonin gene-related peptide (CGRP) receptor antagonist. It is a member of a new class of therapy for the acute treatment of migraine, called the gepants. CGRP is a vasoactive neuropeptide whose receptors are widely distributed in the peripheral and central nervous systems such as the trigeminovascular complex, thalamus, hypothalamus and trigeminal ganglion (Hoffmann and Goadsby, 2012). CGRP has been indicated as a key mediator of migraine pathology by several lines of evidence.

Scope

- Overview of Migraine, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on MK-1602 including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for MK-1602 for the top seven countries from 2012 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Migraine
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of MK-1602 performance
- Obtain sales forecast for MK-1602 from 2012-2023 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan).

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Migraine  - Market Insights, Epidemiology and Market Forecast-2023

Migraine  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • March 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Migraine - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market ...

Dysmenorrhea  - Market Insights, Epidemiology and Market Forecast-2023

Dysmenorrhea  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • March 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Dysmenorrhea - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...

Global OTC Analgesics Market - Growth, Trends and Forecast (2017 - 2022)

Global OTC Analgesics Market - Growth, Trends and Forecast (2017 - 2022)

  • $ 4250
  • Industry report
  • February 2017
  • by Mordor Intelligence LLP

The global OTC Analgesics market accounted for a market value of USD XX billion in 2015. The market is expected to reach USD XX billion in 2016 and USD XX billion by 2021, growing at a CAGR of xx% during ...


Download Unlimited Documents from Trusted Public Sources

The future of the Pain Relief Industry in the UK

  • February 2017
    5 pages
  • Pain Relief  

  • United Kingdom  

View report >

Pain Relief Industry in the US

  • January 2017
    7 pages
  • Pain Relief  

  • United States  

View report >

Pain Relief Industry in the US

  • January 2017
    20 pages
  • Pain Relief  

    Therapy  

  • United States  

View report >

Otc Markets In China

5 months ago

Related Market Segments :

Pain Relief

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.